HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy.

AbstractBACKGROUND AND PURPOSE:
Cisplatin-paclitaxel (TP) combination chemotherapy as the first-line therapy for numerous cancers is hindered by its inadequate accumulation in tumors and severe side effects resulting from non-specific distribution. The aim of this study is to explore whether TMTP1-modified, cisplatin and paclitaxel prodrugs co-loaded nanodrug could improve cervical cancer chemotherapy and relieve its side effects through active and passive tumor targeting accumulation and controlled drug release.
METHODS:
TDNP, with capacities of active targeting for tumors and controlled drug release, was prepared to co-deliver cisplatin and paclitaxel prodrugs. The characteristics were investigated, including the diameter, surface zeta potential, stability and tumor microenvironment (TME) dependent drug release profiles. Cellular uptake, cytotoxicity, drug accumulation in tumors, antitumor effects and safety analysis were evaluated in vitro and in vivo.
RESULTS:
The oxidized cisplatin and the paclitaxel linked to the polymer achieved a high loading effciency of over 80% and TME-dependent sustained drug release. Moreover, TMTP1 modification enhanced cellular uptake of TDNP and further improved the cytotoxicity of TDNP in vitro. In vivo, TDNP showed an extended blood circulation and increased accumulation in SiHa xenograft models with the aid of TMTP1. More importantly, TDNP controlled tumor growth without life-threatening side effects.
CONCLUSION:
Our study provided a novel TP co-delivery platform for targeted chemotherapy of cervical cancer, which was promising to improve the therapeutic effcacy of TP and may also have application in other tumors.
AuthorsGuiying Jiang, Xueqian Wang, Ying Zhou, Chenming Zou, Ling Wang, Wei Wang, Danya Zhang, Hanjie Xu, Jie Li, Fei Li, Danfeng Luo, Xiangyi Ma, Ding Ma, Songwei Tan, Rui Wei, Ling Xi
JournalInternational journal of nanomedicine (Int J Nanomedicine) Vol. 16 Pg. 4087-4104 ( 2021) ISSN: 1178-2013 [Electronic] New Zealand
PMID34163161 (Publication Type: Journal Article)
Copyright© 2021 Jiang et al.
Chemical References
  • Drug Carriers
  • Polymers
  • Prodrugs
  • Paclitaxel
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, metabolism, pharmacology)
  • Cell Line, Tumor
  • Cisplatin (administration & dosage, metabolism, pharmacology)
  • Drug Carriers (chemistry)
  • Female
  • Humans
  • Nanoparticles (chemistry)
  • Paclitaxel (administration & dosage, metabolism, pharmacology)
  • Polymers (chemistry)
  • Prodrugs (metabolism)
  • Tumor Microenvironment (drug effects)
  • Uterine Cervical Neoplasms (drug therapy)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: